title: [Trisomy of chromosome 8 in Ph-negative cells of the bone marrow in patients with chronic myeloid leukemia treated with inhibitors of BCR-ABL tyrosine kinases].
abstract: OBJECTIVE
  To analyse clinical implications of chromosome 8 trisomy in Ph-negative cells of the bone marrow in patients with chronic myeloid leukemia (CML) treated with inhibitors of tyrosinkinases (ITK).
  
  
  METHODS
  A total of 386 patients with CML (chronic phase--288, acceleration phase--77) received imatinib (400-800 mg/day). Because of resistance and/or intolerance some patients were switched to ITK II (nilotinib, dasatinib, bozutinib). This study included 8 CML patients (7 in a chronic phase, 1 in acceleration phase) treated with BCR-ABL ITK inhibitors of the first (imatinib) and the second line (ITK-II). The standard cytogenetic examination, on demand--investigation of the interphase nuclei with FISH, in some cases morphological, cytochemical and histological examinations of the bone marrow were made.
  
  
  RESULTS
  The existence of a Ph-negative clone with trisomy of chromosome 8 had no negative effect on the course of the disease. The patients showed a stable hematological and cytogenetic response and no need in changing treatment policy. In long-term follow-up Ph-negative clone with trisomy of the chromosome 8 persisted without a clear trend to rise in most patients.
  
  
  CONCLUSIONS
  Detection of a Ph-negative clone with chromosome 8 trisomy at early stages suggests parallel existence of Ph-positive and Ph-negative clones. None of the patients had myelodisplasia.
authors.forename: A G
authors.initials: AG
authors.lastname: Turkina
authors.forename: E V
authors.initials: EV
authors.lastname: Domracheva
authors.forename: A V
authors.initials: AV
authors.lastname: Vorontsova
authors.forename: E A
authors.initials: EA
authors.lastname: Aseeva
authors.forename: O Iu
authors.initials: OIu
authors.lastname: Vinogradova
authors.forename: O V
authors.initials: OV
authors.lastname: Stakhina
authors.forename: G A
authors.initials: GA
authors.lastname: Gusarova
authors.forename: O A
authors.initials: OA
authors.lastname: Diagileva
authors.forename: E A
authors.initials: EA
authors.lastname: Semenova
authors.forename: M V
authors.initials: MV
authors.lastname: Vakhrusheva
authors.forename: T I
authors.initials: TI
authors.lastname: Kolosheĭnova
authors.forename: E M
authors.initials: EM
authors.lastname: Abakumov
authors.forename: E Iu
authors.initials: EIu
authors.lastname: Chelysheva
authors.forename: S R
authors.initials: SR
authors.lastname: Goriacheva
authors.forename: T V
authors.initials: TV
authors.lastname: Ivanova
authors.forename: E S
authors.initials: ES
authors.lastname: Zakharova
authors.forename: L Iu
authors.initials: LIu
authors.lastname: Kolosova
authors.forename: A V
authors.initials: AV
authors.lastname: Zakharova
authors.forename: I N
authors.initials: IN
authors.lastname: Naumova
authors.forename: L V
authors.initials: LV
authors.lastname: Diachenko
authors.forename: S M
authors.initials: SM
authors.lastname: Kulikov
authors.forename: L G
authors.initials: LG
authors.lastname: Kovaleva
authors.forename: N D
authors.initials: ND
authors.lastname: Khoroshko
mesh_terms: D000328:Adult; D001549:Benzamides; D001854:Bone Marrow Cells / Q000187:drug effects* / Q000201:enzymology / Q000473:pathology; D002898:Chromosomes, Human, Pair 8 / Q000235:genetics*; D004334:Drug Administration Schedule; D005260:Female; D016044:Fusion Proteins, bcr-abl / Q000037:antagonists & inhibitors*; D006801:Humans; D000068877:Imatinib Mesylate; D007621:Karyotyping; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000201:enzymology / Q000235:genetics; D008297:Male; D008875:Middle Aged; D010677:Philadelphia Chromosome / Q000187:drug effects*; D010879:Piperazines / Q000008:administration & dosage / Q000627:therapeutic use; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D011743:Pyrimidines / Q000008:administration & dosage / Q000627:therapeutic use; D013997:Time Factors; D014314:Trisomy
chemical_list: D001549:Benzamides; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D016044:Fusion Proteins, bcr-abl; C498826:nilotinib